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GENERAL INTRODUCTION 
Cycloplazonlc acid Is a toxic secondary metabolite produced by sev­
eral different species of the fungal genera, Pénicillium and 
Aspergillus» The toxicity of CPA has been demonstrated In several 
animal species Including rats,^  mlce,^  ^ guinea plgs,^  ^
18-23 24 25 26 27 
chickens, dogs, rabbits, pigs, and monkeys. The known 
clinical signs Include decreased weight gain, diarrhea, dehydration, de­
pression, opisthotonos, convulsions, hyperesthesia, hypoklnesls, voml-
tlon, and death. Lesions resulting from CPA administration have oc­
curred In the gastrointestinal tract, liver, kidneys, spleen, pancreas, 
salivary glands, heart, and skeletal muscle. The extent of CPA con­
tamination of food and feed has not been fully evaluated; however, corn, 
peanuts, and cheese have been shown to be naturally contaminated with 
CPA.28-31 
The role of CPA In animal and human disease has not been estab­
lished. However, because of the number and variety of fungal species 
that produce CPA, and because many of these fungi are present In crops 
of worldwide Importance such as peanuts and corn, this mycotoxln merits 
toxlcologlcal Investigation. 
This study was undertaken because no toxicity studies have been 
conducted with turkeys. Both vitro and dm vivo evaluations were 
conducted to evaluate cardiac effects of CPA. Physiological parameters, 
histological and ultrastructural evaluations were conducted. This 
dissertation consists of a series of manuscripts to be submitted to the 
2 
American Journal of Veterinary Research. A general summary and dis­
cussion follows the last manuscript. Literature cited In the disserta­
tion, Introduction, literature review, general summary, and discussion 
appear at the end of the dissertation. 
3 
LITERATURE REVIEW 
Historical and general chemical perspective Scientific study of 
the mycotoxln, cycloplazonlc acid (CPA) has spanned 25 years* Cyclo-
piazonlc acid was initially Identified in 1968 during a metabolite 
32 
screening study of Pénicillium cultures. Retrospectively, CPA was in­
criminated in turkey deaths observed in the "turkey X" disease outbreak 
of 1960. Initial experimental work with CPA began in 1971 when 
Purchase^  determined the oral (po) and Intraperitoneal (Ip) LD^ g for 
rats. 
Cycloplazonlc acid has been characterized as an Indole tetramic 
acid that acts as a mono-basic acid. Cycloplazonlc acid is derived 
from one molecule of tryptophan, one molecule of mevalonic acid, and 
two molecules of acetic acid. Its molecular weight is 336.15 and mo-
32 34 35 lecular formula is C^ g Ng Og. ' ' From methanol extracts crys­
talline CPA can be Isolated and it has a melting point of 245 -
246°C.3*'37 
Cycloplazonlc acid is produced by several species in the genera 
Pénicillium and Aspergillus. Natural contamination with CPA has been 
28 29 30 31 38 determined in corn, peanuts, and cheese. ' ' There is pre­
sumptive evidence that CPA could be present in a number of other com­
modities because they contained CPA-producing fungi. These commodities 
Included: navy beans, pinto beans, corn meal, macaroni, pecans, wal­
nuts, ham, sausage, and frankfurters. 
4 
Presently several œthods are utilized for analytical detection of 
CPA and Include thin-layer chromatography,^ ®nuclear magnetic 
42 
resonance analysis, reversed phase high-performance liquid chroma-
29 43 
tography, and normal phase high-performance liquid chromatography. 
A simple colorlmetric method for screening CPA in agricultural com-
44 
moditles was recently reported. 
Cycloplazonlc acid is readily absorbed from the gut, with rapid 
distribution and excretion in rats. Following administration of radio­
labeled CPA, a half life of 33 12 hours was established for intra­
peritoneal and 43 + 12 hours for intragastric exposures. CPA was found 
in various tissues but no bioaccumulation occurred in tissues. The 
highest levels of CPA were found in blood, skeletal muscle and liver, 
respectively. Biliary excretion had a major role in CPA excretion in 
feces.^  
The mutagenic activity of CPA has been studied in Salmonella 
45 typhlmurlum and the results are contradictory; Wehner ^  al. reported 
46 CPA had no mutagenic response. However, Sorenson et al. reported a 
47 positive response. An older report suggested that CPA may be carci­
nogenic and responsible for liver carcinomas in Bantu tribes of Africa. 
Teratologic studies have been conducted with mice, rats, and chickens. 
No teratogenic effects were observed in rats and mice; however, terato­
genic effects were observed In 2-day old chicken embryos in which the 
19 
caudal end of trunk was shortened and microphthalmia occurred. 
Toxicity The acute oral In male rats given CPA is 36 mg/ 
kg and 63 mg/kg for females. The intraperitoneal (Ip) LD^ g for male 
5 
rats Is 2.3 mg/kg.^  The Ip LD^ g in male mice was found to be 13 
12 fflg/kg. The acute oral LDgg in day-old cockerels was found to be 
21.71 mg/kg.^ * Another study determined a 72-hour LD^ Q of 12.0 mg/kg 
23 for male broiler chicks and 12.1 mg/kg for females. 
The response to CPA is both species and dose related. Synopsis of 
several studies with CPA that have produced variable results depending 
on the species of experimental animal, sex, route, dose, carrier, and 
duration of administration are shown in Table 1. 
Pathophysiology Animals exposed to CPA usually show: (1) clin­
ical pathological changes; (11) gross pathological changes; and (ill) 
microscopic alterations. 
(1) Clinical pathological changes. Changes in some clinical 
pathological values following CPA exposure have been reported in 
20 23 24 17 6 
chickens, ' dogs, guinea pigs, and rats. Chicks gavaged with 
2 or 4 mg/kg of CPA in corn oil had Increased plasma creatinine kinase 
20 
activity that correlated with skeletal muscle degeneration. In a 
similar study, a dose-related decrease in hematocrit, plasma potassium 
and protein was noted in chicks dosed with CPA at 1, 2 or 4 mg/kg for 
23 23 days. In guinea pigs exposed to CPA at doses ranging from 0.00625 
to 1.95 mg/day for 30 days, the most remarkable changes In any measured 
parameter were in the serum enzyme concentrations. The aspartate 
amino-transferase (AST), alanine aminotransferase (ALT) and sorbitol 
dehydrogenase (SDH) concentrations were Increased, but only in the ani­
mals given 1.6 and 1.95 mg CPA/day. Total serum bilirubin concentration 
Increases were slightly elevated with Increasing doses of CPA. Total 
6 
Table 1. Experimental Toxicity of CPA for Pigs, Poultry, and 
Laboratory Animals 
Species Route/Dose Duration Clinical Signs Reference 
Piglets po/ 10 mg/kg 14 days Anorexia, 
inactivity, 
rough hair 
coat, weakness 
Lomax et 
«a. 1984 
Piglets po/ 1 mg/kg 14 days Inactivity, 
rough hair 
coat 
Lomax et 
1^. 1984 
Chicks po/ 4 mg/kg 23 days Deaths Cullen et 
al. 1988 
Chicks po/100 ppm 49 days Deaths, de­
creased 
weight gain 
Dorner et 
1983 
Chickens po/ 10 
po/ 5 
mg/kg 
mg/kg 
4 days Decreased 
weight gain 
Norred et 
1988 
Chicks po/ 4 mg/kg 23 days Decreased 
weight gain, 
feed and water 
intake 
Wilson et 
al. 1986 
Dogs po/ 1 
po/ 0.5 
mg/kg 
mg/kg 
90 days Deaths, 
anorexia, 
vomiting, 
diarrhea, 
weight loss, 
pyrexia, 
depression 
Neuhring 
et al. 
1985 
Monkeys po/ 20 mg/kg 112 days Sporadic 
emesls, 
no weight gain 
Jasklewlcz 
et al. 
1988 
Rabbits ip/ 10 mg/kg _<1 day Tachycardia, 
dyspnea, 
death 
Nlshle et 
al. 1985 
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Table 1 (Continued) 
Species Route/Dose Duration Clinical Signs Reference 
Mice 
Mice 
Rats 
Rats 
Rats 
Ip/ 11 & 6 days 
14 mg/kg 
Ip/ 10 mg/kg 1 day 
Ip/ 8 mg/kg _<1 day 
po/ 30 to 
83 mg/kg 
1.5 -
2 days 
po/ 8 mg/kg 4 days 
ip/ 5 mg/kg 28 days 
Guinea po/1.6 & 30 days 
pigs 1.95 mg/day 
Complete feed Nishie et 
and water re­ 1985 
fusal, tremor, 
prostration. 
ptosis, death 
Catalepsy, Nishie et 
weight loss 1985 
Ataxia, Purchase 
death. 1971 
prostration. Purchase 
death 1971 
Diarrhea, Morrissey 
nasal dis­ et al. 
charge, rough 1985 
hair coat. 
ataxia, 
lethargic. 
deaths 
Diarrhea, Hill et 
dehydration 1986 
Death, Richard 
anorexia. et al. 
rough hair 1986 
coat, ataxia. 
pain upon 
movement, 
diarrhea 
8 
protein and albumin concentrations were not changed, except a slight 
Increase was noted in the animals given 1.6 and 1.95 mg/day.^  ^ In rats 
exposed to 8.0 mg/kg for 4 days, serum AST and ALT were elevated, cyto­
chrome P-450 was decreased and glutathione S-transferase was unchanged. 
No serum chemical changes were noted in the rats given 0.2, 2.0, and 
6 8 4.0 mg/kg/day. Hill et al. reported that in rats given 0.1, 1.0, and 
5.0 mg/kg for 28 days, total protein, albumin, PCV and hemoglobin val­
ues were not significantly altered. The rats given 1.0 and 5.0 mg/kg 
had higher mean neutrophil counts and lower mean eosinophil and lym­
phocyte counts than did controls. Cyclopiazonic acid did not affect 
the degree of cellularity, myeloid to erythroid ratio and presence of 
all stages of maturation in bone marrow smears. Dose-related clinical 
pathologic changes in dogs dosed at 0.05, 0.5 and 1.0 mg/kg, consisted 
of leukocytosis, neutrophilia, lymphopenia, monocytosis and increased 
24 
serum alkaline phosphatase activity. Pigs treated with CPA at doses 
ranging from 0.01 to 10 mg/kg, showed no changes in PCV, plasma protein 
hemoglobin, serum calcium,'phosphorus and magnesium, total protein, al­
bumin, blood urea nitrogen, serum alkaline phosphatase, AST, and gamma 
glutamyl transpeptidase. 
(11) Gross pathological changes. Relatively few gross lesions 
have been observed in animals following exposure to CPA. Splenic 
changes Including atrophy, necrosis, hemorrhage and mucosal erosions in 
12 6 
the gastrointestinal tract have been reported in the rat. ' ' In 500 g 
guinea pigs given 1.6 and 1.95 mg/d, superficial necrosis of the gastric 
mucosa was the significant lesion reported.Chickens fed 50 or 100 
9 
ppm had lesions In the gastrointestinal tract. Thickened mucosa and 
dilated lumens were noted in the proventricull of birds fed 50 ppm. 
Birds from the 100 ppm group had proventricular mucosal erosions and 
hyperemia. Splenic necrosis was reported in both 50 and 100 mg/kg 
18 birds. Similar gross lesions including; hemorrhage, necrosis and 
hyperplasia of proventricular mucosa were reported in chickens gavaged 
20 
with CPA. Dogs appear to be very susceptible to CPA. Oral doses of 
1.0 mg/kg caused death at 48 h. Gross lesions were frequently observed 
in kidneys and the gastrointestinal tract. Kidney lesions included 
raised circular infarcts. Ulceration of the soft palate, esophagus and 
gastrointestinal tract was seen. Other lesions observed were nuclear 
enlargement in the bladder, epithelium and adrenal glands, and necrosis 
in the skin and epididymis.Lomax et al.^ * reported lesions in 1 and 
10 mg/kg treated piglets. Lesions were most prominent in the kidneys 
and gastrointestinal tract. Gross lesions of gastric hemorrhage, ulcer­
ation and mucosal hyperemia were observed InT both the large and small 
intestines. No gross lesions were reported in monkeys given up to 60 
mg/kg. 
(ill) Microscopic alterations. Target organs vary in different 
laboratory animal species treated with CPA. Rats given oral doses from 
2.5 to 8.0 mg/kg had liver changes that were dose related progressing 
from single cell necrosis to multiple foci of necrosis. Changes in 
bile ducts Included karyomegaly and swollen cells that occluded the 
duct. Bile duct epithelial necrosis was reported at 4.5 mg/kg. 
10 
Pancreatic changes Included necrosis of acinar cells, vacuolar degener­
ation and pyknosls of Islet cells.In a low dose (0.1 to 5.0 
mg/kg) chronic study Involving rats, only hepatic and renal changes were 
noted. Changes Included vacuolated and granular hepatocytes, dilated 
g 
renal tubules with pyknotic nuclei and a few scattered casts. In 
addition to renal and hepatic lesions, salivary gland changes consisting 
of swollen serous and ductular epithelial cells, with clear nucleoplasm 
3 
and prominent nucleoli were reported in rats orally dosed for 21 days. 
In two studies of chickens orally exposed to CPA, gastrointestinal 
18 
changes were the most remarkable. Dorner et al. reported mucosal epi­
thelial necrosis and inflammation in the crop, proventriculus, and ven-
trlculus. Hepatocellular vacuolatlon and skeletal muscle degeneration 
20 
also were reported following CPA gavage. Guinea pigs had lesions sim­
ilar to those seen in rats, including gastric mucosal necrosis and hepa­
tocellular vacuolatlon at CPA doses of 1.6 and 1.95 mg/day.^  ^ Piglets 
given oral CPA at 10 mg/kg/d had microscopic lesions in gastric and in­
testinal mucosa, liver and kidneys. Gastric mucosal Inflammation and 
necrosis, villous blunting, and mucosal hyperemia and hemmorhage in both 
large and small intestinal tracts was noted. Only mild focal gastric 
26 
mucosal necrosis was seen in piglets dosed at 1.0 mg/kg/d. 
Dogs are the most sensitive species that have been tested for 
toxicity to CPA. In feeding studies conducted with dogs, CPA levels of 
0.1, 1.0 and 2.0 mg/kg were administered. The major dose-related 
microscopic lesions seen in different tissues were categorized as: 
vascular damage, ulceration accompanied by necrosis, and necrosis with 
11 
karomegaly> Ulcerative and necrotic lesions were associated with vas­
cular damage In all systems, except for the lymphoid organs. Vascular 
Injury was random and segmental with changes that Included: swollen 
vacuolated endothelial cells, acidophilic granular material between the 
endothelium and Internal elastic membrane, loss of endothelial cells, 
occurrence of fibrin In the tunica media, vacuolation of myocytes of 
the tunica media and infiltrates of esoslnophlls and neutrophils. 
Severely affected vessels had foci of necrosis, hemorrhage and neutro­
phils in the intima and media. Gastrointestinal erosions and ulcers 
had surrounding mucosal lamina propria that was hyperemlc, edematous 
and infiltrated with neutrophils. Necrosis was observed in kidneys, 
livers and lymphoid tissues of the 1.0 mg/kg dogs. Karyomegaly was ob­
served in the liver, kidney, gastrointestinal tract, urinary bladder 
24 
epithelium and adrenal glands. In monkeys exposed to levels of CPA 
up to 60 mg/kg/d for 16 weeks, microscopic lesions were mild and ir­
regular. Mild karomegaly of biliary and pancreatic duct epithelial 
cells, and renal medullary tubules were noted; minute tubular atrophy 
27 
and protein casts were present. 
Liver, cardiac, and skeletal muscle ultrastructural changes have 
been reported following exposure to Oral dosages of 2.0 
and 4.0 mg/kg/day resulted in swollen mitochondria and vesiculatlon of 
the rough endoplasmic reticulum In rat livers.^  Ultrastructural 
changes were also reported in guinea pigs receiving total dosages of 4, 
8, 12, and 16 mg/kg. Limited mitochondrial swelling was found in guinea 
pigs given the lower doses. Animals that received 12 and 16 mg/kg 
12 
showed a dose response In severity and degree of dilated sarcoplasmic 
reticulum, swollen mitochondria and segmental necrosis in gastrocnemius 
and vastus lateralis musculature.^  ^ Unusual irregular thickening and 
cytoplasmic vacuoles or abnormally large fenestrations were the most 
pronounced ultrastructural changes found in cardiac capillary endo­
thelium and kidneys of monkeys exposed to CPA. Cytoplasmic processes 
of long, Irregular foldings were noted. Some capillary endothelium 
appeared to be separated from the basal membrane with accumulation of 
homogenous substance in the subendothelial space. Myocytes had focal 
lysis of myofibrlllae, mitochondrial accumulation and lysosome for-
27 
mations. Hepatocytes had dilated rough endoplasmic reticulums. 
Cardiac pathophysiology Several studies reported that CPA pro­
duced lesions in or altered function of the heart. Purchase^  first re­
ported cardiac lesions of hyaline or coagulative degeneration of rat 
myocardium following CPA exposure to oral dosages ranging from 30 to 
82.6 mg/kg. Findings In a distribution study indicated that heart, a-
long with lungs, kidneys, liver, and skeletal muscle were the tissues 
with the greatest amounts of labelled CPA.^  Altered cardiac function 
reported in rabbits exposed to 5.7 or 10 mg/kg of CPA was characterized 
by tachycardia followed by bradycardia and terminal ventricular fibril­
lation.^  ^ Negative Inotropic effects in Isolated frog ventricles were 
observed 30 seconds after exposure to 20 ug/ml of CPA.*^  In chickens, 
fed 50 and 100 ppm dietary CPA on an ad libitum basis, there was sub­
acute to chronic inflammation of the eplcardlum and chronic myocardial 
18 Inflammation noted at both dosing levels* Decreased heart muscle 
13 
mass was reported In broiler chicks orally exposed to CPA at 1, 2, 4, 
23 8, and 16 mg/kg. Other myocardial pathological effects have included 
cellular degenerative changes of enlarged pleomorphic nuclei, with 
nargination of chromatin following weekly CPA dosages of 12 or 21 mg/kg 
3 in rats. Myocardial lesions were present in two monkeys treated with 
CPA; doses up to 60 mg/kg caused lesions of focal degenerative cellular 
27 
changes, focal atrophy and cellular disarray were reported. In con­
trast, no heart lesions were noted in CPA studies where oral dosages 
were 4 mg/kg in rats;^  ^1, 2, or 4 mg/kg in broiler chicks;^ ® 0.05, 
0.25, 0.5, or 1.0 mg/kg in dogs;^ * and 0.01, 0.1, 1.0 or 10 mg/kg in 
piglets. 
Cyclopiazonic acid in vitro assays In vitro experiments uti­
lizing CPA have included tissue preparations of esophagus, jejunum, 
ileum, trachea, aorta, vas deferens, uterus, ventricles, cell cultures 
of rat hepatocytes and pig kidney epithelial cells and sarcoplasmic 
reticulum vesicles from rat skeletal muscle.Cyclopiazonic acid 
enhances peristaltic movement of the jejunum, ileum, and estrous uterus 
and produced broncho-constriction Jji vitro. The inotropic effects of 
dopamine, epinephrine and serotonin in vas deferens were not blocked by 
CPA. These findings indicated that the reported toxic effects of CPA 
(hypothermia, catalepsy, hypokinesia, and tremor) probably were not due 
to neurotransmitter-receptor blockage.Altered membrane permeability 
or alteration of ion pumps were hypothesized to be the mechanism of 
action when CPA stimulated accumulation of a transmembrane potential 
14 
probe, tetraphenylphosphonlum bromide (TPF), in cultured pig kidney 
49 
renal epithelial cells. 
Subsequent studies utilized inhibitors of TP? accumulation and 
fractionation of renal epithelial cell to examine CPA membrane effects. 
Cells accumulated TTP in plasma membrane and mitochondrial fractions 
when exposed to CPA. Control cells accumulated TPP in the cytosol. 
These findings suggested that CPA may: (1) combine with TPP within 
membranes, (2) act as a TPP carrier, or (3) create a negative electro-
49 51 
static potential within membranes. ' Other studies have also shown 
that CPA alters calcium flux in renal epithelial and skeletal muscle 
cells^  ^and is a potent Inhibitor of calcium ion transport and calcium 
52 ATP-ase in rat skeletal muscle sarcoplasmic reticulum. 
In other studies utilizing CPA alone or in combination with afla-
toxin there has been negative or equivocal results on Immunological 
function. 
15 
SECTION I. IN VITRO EVALUATION OF ISOLATED TURKEY CARDIAC MUSCLE 
FUNCTION 
16 
In Vitro Evaluation of Isolated Turkey Cardiac Muscle Function 
C. D. Miller^ , DVM, MS, F. B. Hembrough^ , DVM, PhD, J. L. Richard^ , PhD, 
G. D. Osweller^ , DVM, PhD 
N^ational Animal Disease Center, Agricultural Research Service, 
United States Department of Agriculture, P. 0. Box 70, Ames, lA 50010. 
2 Department of Veterinary Physiology and Pharmacology, College of 
Veterinary Medicine, Iowa State University, Ames, lA 50011. 
3 Veterinary Diagnostic Laboratory, College of Veterinary Medicine, 
Iowa State University, Ames, lA 50011. 
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SUMMARY 
Turkey papillary muscles can function for up to six hours In an 
Isolated chamber containing oxygenated, pH-regulated, modified Krebs-
Henselelt solutions. Our data Indicate that different calcium con­
centrations affect muscle contraction and relaxation velocities, load 
values, and latencies. This controlled In vitro biological assay system 
can be used In further studies to evaluate species specific cardiac 
toxins or drugs. 
18 
INTRODUCTION 
1**4 Papillary muscles from a number of species Including: cats, 
dogs,^ "* plgs,^  rats,® guinea pigs,* rabblts,^ ®"^  ^ferrets,and 
13 hamsters have been utilized to study cardiac mechanics. Additionally, 
these muscle preparations have provided an vitro evaluation of the 
physiological and pharmacological effects of toxlnsl, drugs, and 
hormones^ * on cardiac function. There has been comparatively little 
work done with Isolated cardiac muscle preparations from the avian 
species. A turkey cardiac muscle ^  vitro assay system will provide 
additional avian cardiac mechanics data and a means to study known, sus­
pected, or specles-speclflc cardlotoxlns. 
The objectives of this study were to determine the experimental con­
ditions and techniques that would optimize ^  vitro turkey papillary 
muscle function. We have reported on Initial Investigations that dealt 
with muscle harvest techniques, solution modifications and temperature 
evaluations for optimal muscle function.Specific attention was 
directed towards defining optimal calcium concentration and appropriate 
evaluation criteria. This report provides baseline Information on In 
vitro function of turkey papillary muscle preparations. 
19 
MATERIALS AND METHODS 
Turkey papillary muscle preparation Twenty turkey poults (8-14 
weeks old. Broad Breasted White) were anesthetized with sodium pento­
barbital (65 mg/kg). The heart was removed and left ventricular 
papillary muscles were rapidly cut to the dimensions of 1 mm X 1 mm X 
17 18 7-10 mm while the tissue was Immersed In an oxygenated, modified 
Krebs-Henselelt (K-H) solution. 
Equipment Papillary muscles were mounted vertically In the 
Inner chamber (10 ml) of a double chambered constant-temperature bath as 
shown In Figure 1. The non-tendinous end of the muscle was mounted In a 
luclte clamp. The tendinous end was secured In a stainless steel hook 
with sliding clamp. This hook was attached to a silver chain whose 
distal end was connected to an aluminum lever mounted on a Brush trans­
ducer. The muscles were suspended In a modified K-H solution with the 
following basic composition (mM): NaCl (118); KCL (4.7); MgClg (1.2); 
(11): NaHCOg (24.0); CaClg' GHgO (1.7); glucose (4.5); 
pH 7.40. The chamber fluid was varied by changes in calcium concentra­
tions. Arbitrary values of 5.5 mM, 4.32 mM, 3.5 mM, and 1.7 mM calcium 
were utilized. These values were based on literature values, experi­
mental results primarily from dog papillary muscles, and preliminary 
turkey papillary muscle experiments. 
Circulation of the chamber fluid was accomplished through the use 
of an individual rate-controlled pump. The K-H solution was pumped from 
the chamber via a stainless steel tube (20 ga) mounted on the end of the 
Figure 1. Schematic diagram of the chamber for turkey papillary 
muscle bloassay studies 
21 
Oi+COi Electrodes 
Inner Chamber Muscle 
22 
Inner muscle chamber Just below the fluid surface, into the pH monitor­
ing chamber. A roller pump returned the fluid to the muscle chamber via 
a second stainless steel tube (20 ga). This tube was mounted directly 
under the muscle. The total system required 10.5 to 11.0 ml of fluid. 
The fluid was aerated by bubbling 95% Og - 5% COg into the K-H solution 
in the mounting chamber. Fluid pH was continuously measured and temper­
ature was maintained at 31" C. 
A 4-channel Beckman polygraph R-611 (No. 611, Beckman Instruments 
Inc., Electronic Instruments Division, Dept. 205, 3900 River Road, 
Schiller Park, IL) was used to record time, muscle contraction, and 
stimulus applied to the muscle. 
Contractile studies Muscles were allowed to stabilize for 2-
2 1/2 hours while contracting isotonically in K-H solution. Following 
stabilization, the length of muscle that produced maximal contraction 
(L max) was determined for each muscle preparation. The procedures for 
19 determining L max and 90% L max were the same as previously described. 
Seven parameters of muscle function were obtained from afterloading 
turkey papillary muscles. These parameters were: the maximum weight a 
muscle could lift (P^ ); maximum contraction and relaxation velocities (V 
max); time delay or latency between electrical stimulation and initi­
ation of contraction (Lat 1), peak contraction (Lat 2), or completion of 
contraction (Lat 3) and distance a weight was lifted (Work). V max was 
determined by the Hill equation from contraction or relaxation values 
generated by each afterload curve. Latency values were measured from 
one weight that corresponded to the preload weight or 90% L max weight. 
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Latency values were also derived from the contraction curves as shown In 
Figure 2. Each set of muscle afterload data was normalized by length, 
cross-sectional area, and for each muscle. 
Solution studies The experimental (K-H) solution was prepared 
on the experimental day. Osmolarlty and pH were recorded. At the com­
pletion of a 2 to 2 1/2 hour isotonic stabilization period and preload 
determination, the K-H solution was changed. Solution pH was maintained 
at 7.4. The muscle was allowed to equilibrate for a 20 minute period in 
the fresh K-H solution and an afterload curve was generated. Five 
muscles were tested with each solution before the next solution was 
utilized. The order of experimental completion was 5.5 mM, 4.32 mM, 
3.5mM, and 1.7 mM calcium in K-H solutions. 
Statistical analysis Afterload curve contraction and relaxation 
velocity data were fit to a 3rd degree polynomial equation. Analysis of 
variance was used to compare the average V max, P^ , Work, and latency 
values. 
Figure 2. Evaluation parameters for latency from turkey papillary 
muscle bloassay contraction recordings. LÂT 1 - time 
to onset of contraction; LAT 2 - duration of contraction; 
LAT 3 - total duration of contraction and relaxation 
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RESULTS 
The normal plasma values obtained from our preliminary evaluations 
of young turkeys (Table 1) were the criteria used In developing the 
modified K-H solution utilized In this study. The effects of altering 
calcium concentrations on muscle performance are shown In Table 2. 
These afterload data Indicate that there were significant differences 
among the means of four parameters (P^ , V max, Work, Lat 3) and no sig­
nificant differences among the Lat 1 and Lat 2 means. Mean comparisons 
for each group of the five significant calcium related effects are shown 
graphically in Figure 3. Comparisons were considered significantly 
different at the P ^  .05 level. P^  comparisons indicated that the 1.7 
mM calcium group was significantly lower than the other treatment groups. 
There were no differences between the 3.5 mM, 4.32 mM, or 5.5 mM calcium 
means. 
We found that both the maximum contraction and relaxation velocities 
data showed 5.5 mM, 4.32 mM, and 3.5 mM calcium groups were significantly 
different from each other. There were no differences among 1.7 mM and 
3.5 mM calcium groups but graphically there was a decreasing trend. 
The 5.5 mM and 1.7 mM treatment groups were significantly different 
from the two other calcium groups when comparing the muscles's ability to 
do work. There was no difference among the 4.32 mM and 3.5 mM calcium 
groups. 
The 5.5 mM calcium group was significantly lower than the other 
groups when measuring Lat 3. There were no significant differences among 
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Table 1. Mean normal plasma values of total glucose and selected 
elements from young turkeys (8-14 wk.) 
â b 
Determination Normal Value * 
Calcium^  12.6 + (00.6) mg/100 ml 
Magnesium 2.3 + (00.3) mg/100 ml 
Glucose 235.0 + (59.0) mg/100 ml 
Sodium 154.0 + (16.0) meq/1 
Potassium 5.2 + (00.9) meq/1 
 ^Numbers In brackets represent standard deviations. 
 ^Based on N - 25 birds. 
Normal value expressed In mM is 3.09 + 0.15. 
Table 2. Mean contraction and relaxation velocities, work and latency afterload values in 
response to different calcium concentrations from turkey poult papillary muscles 
Calcium Concentration (mM) 
]j;70 4^ 5.50 
Contraction 
Maximum Velocity 
(mm/sec/CSA)**^ *^  0.40 + 0.08 0.49 + 0.14* 0.89 + 0.22* 2.03 + 0.29* 
Relaxation 
Maximum Velocity 
(mm/sec/CSA)*'^ '^  0.29 + 0.05* 0.51 + 0.07* 0.92 + 0.13* 2.93 + 0.31* 
P^  (mg)*'='d 0.21 + 0.04* 0.34 + 0.05 0.34 + 0.09 0.30 + 0.06 
Work (mgs'mm/CSA)®**^  60.70 + 10.60* . 159.00 + 21.30 173.00 + 36.20 394.00 + 105.20* 
Latency 1 (mm)*^  1.58 + 0.16 1.55 + 0.29 1.65 + 0.45 1.55 + 0.40 
Latency 2 (mm)*^  7.10 + 0.44 7.23 + 0.30 6.93 + 0.47 6.75 + 0.13 
Latency 3 (mm)*^  11.40 + 0.69 10.90 + 0.18 10.80 + 0.27 9.85 + 0.47* 
 ^Normalized for muscle cross sectional area (CSÀ). 
 ^Maximum contraction and relaxation velocities are y intercepts, determined by plotting 
velocity vs load. 
^ Mean and S.E.M. 
is the maximum weight a muscle could lift. 
Value significantly different (P < 0.05) from 3 other groups. 
 ^Value significantly different (P ^  0.0001) from 1.7 mM group. 
to 
t 
Value signficantly different (P ^  0.001) from 2 other groups. 
§ 
Value significantly different (P 0.001) from 3 other groups. 
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the other calcium groups when measuring Lat 3, but there was a trend 
towards faster completion of contraction with Increasing amounts of 
calcium. 
Figure 3. The effects of calcium on afterload performance parameters 
(means + SEM) of turkey papillary muscle bloassays 
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DISCUSSION 
This work shows that turkey papillary muscles can be harvested, 
transected and remain functional for up to 6 hours In an Ijn vitro cham­
ber. Anatomically papillary muscles In the turkey heart are not as well 
developed as other species, I.e., cats, rabbits, and dogs. Nevertheless, 
preliminary studies showed that the harvest techniques which Included 
quick transection will produce uniform muscle preparations.^  ^
A modified K-H solution was developed that provides a suitable 
matrix for cardiac muscle function studies. Normal clinical pathology 
20 21 
values of mature turkey plasma were available from the literature ' 
but were not found for young poults. Therefore, normal plasma bio­
chemical values were determined for immature birds (Table 1) as a pre­
requisite to establishing the composition of a suitable K-H solution for 
muscle preparations from young poults. Several variables associated with 
K-H solutions Influence isolated papillary muscle performance. These 
variables Include temperature, pH, calcium ion concentration, and 
oxygenation.^ ®' 
The effect of temperature on papillary muscle performance has been 
22 23 24 25 
a source of controversy. ' ' ' The physiological temperature of 
turkeys is approximately 42* C suggesting that in vitro muscle perform­
ance might be ideal at similar temperatures. Our early studies comparing 
37° C and 31° C showed that and relaxation velocities were reduced at 
37° C temperatures.^  ^ Papillary muscles studied at lower temperatures 
(31° C) may be responding to the or temperature coefficient Involved 
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In the velocity of enzyme-catalyzed reactions. The velocity of many bio­
logical reactions roughly doubles with a 10° C rise In temperature. The 
effective operational temperature of 31° C prolongs the working life of 
an Isolated muscle. 
Turkey papillary muscle data compares well with other studies In our 
19 25 26 laboratory Involving the dog. ' * Dog afterload velocity data were 
fit to 3rd power equations to establish V max and values. Turkey 
afterload velocity data were best fit to a 3rd degree polynomial and Hill 
equations to determine V max values. A typical Individual muscle after-
load curve, demonstrating relaxation data fit to a 3rd degree polynomial 
and Hill equations Is shown In Fig. 4. This curve exemplifies a fre­
quently but unexplalnable observation of a decreased relaxation V max 
when compared to contraction V max. This Is also seen In the group mean 
values (Table 2). Muscle tension development undergoes depression with 
acidosis. In our laboratory, pH ranges that satisfactorily supported 
dog muscle preparations worked equally well for turkeys. K-H solution 
pH for turkeys closely correlates with physiological pH and other re- * 
27 28 
searchers' findings of an operational range of 7.25 - 7.60. * 
The ability of turkey papillary muscles to perform and function In 
K-H solutions with different calcium concentrations compared well with 
19 29 4 12 young dogs ' and other species. ' Mean values for 1.7 and 3.4 
mM calcium showed a linear, almost doubling relationship. The reduced 
P^  mean value for the 5.5 mM calcium group could be due to partial cal­
cium toxicity. Normal turkey plasma values of total calcium are approxi­
mately 3.1 mM. Normal papillary muscle tissue concentrations of free or 
Figure 4. Typical contraction and relaxation afterload curves 
generated by a turkey poult papillary muscle in 
4.32 mM calcium. Data are fit to a third degree 
polynomial equation. The Hill equation was used 
for V max determinations 
36 
1.3 
1.2-1 
CONTRACTION VELOCITY 
RELAXATION VELOCITY 
< 1.0-
^ 0.9 
0.8-
E 0.7-
— 0.6-
ë 0.5-
§ 0.4-
g 0.3-
0.2-
0 1 -
0 -
0.1 0.2 0.3 0.4 0.5 0.6 0.7 08 0.9 1.0 
LOAD (P/Po) 
37 
unbound Intracellular calcium would be more nearly approximated by the 
1.7 mM concentration. This logic could partially explain the reason 
that experimental muscles In the 5.5, 4.3, and 3.5 mM calcium groups 
were observed to be slower to adapt to experimental conditions when 
Initially placed In the ^  vitro chamber. 
• Recent studies have been concerned with chemical or drug effects on 
30 31 32 the dynamics of avian cardiac mechanics. ' ' Our study demon­
strates that the turkey papillary muscle evaluation system could be uti­
lized to provide preliminary Iji vitro evaluation of chemicals and drugs 
prior to clinical trials, pathophysiological data, or Intermediate cor­
relations between cardiac cell cultures and In vivo application. 
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SUMMARY 
An ^  vitro bloassay system was utilized to study the effects of 
cycloplazonlc acid mycotoxln on cardiac muscle. Acute exposure to CPA 
at 6 ug/ml significantly decreased five parameters of 1a vitro papillary 
muscle performance. The five performance criteria Included; P^ , maximum 
contraction and relaxation velocity, time to peak contraction, and 
total time for muscle contraction and relaxation. These altered per­
formances appear to be Intracellular changes partially associated with 
calcium availability and were Irreversible suggesting that physlo-
pathologlcal changes had occurred following acute CPA exposure. 
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INTRODUCTION 
Cycloplazonlc Acid (CPA) Is a mycotoxln produced by a number of the 
genera Aspergillus and Pénicillium.^  Studies indicate that CPA is 
quite prevalent In corn and peanuts; however, the potential mycotoxl-
cologlcal problem has not been established. Foods and feeds of both 
humans and animals have been shown to contain CPA.^  ^  Therefore, CPA 
represents a potential toxicologlcal problem of agricultural and eco­
nomic significance. 
Among other physiological and pathological changes, CPA alters 
cardiac function. Rabbits exposed to 5, 7, and 10 mg/kg demonstrated 
tachycardia followed by bradycardia and terminal ventricular fibril­
lation. Negative Inotropic effects in Isolated frog ventricles were ob­
served 30 sec after exposure to 20 ug/ml of CPA.* Purchase^  reported 
hyaline or coagulatlve degeneration of rat myocardium following oral 
doses ranging from 36 mg/kg in males to 63 mg/kg in females. Other 
myocardial pathological effects following weekly CPA doses of 12 or 21 
mg/kg in rats, have included cellular degenerative changes of enlarged 
Q 
pleomorphic nuclei with marglnation of chromatin. 
An ^  vitro biological assay system that utilizes turkey cardiac 
muscle was utilized to investigate CPA cardiac effects. The system was 
effective for measuring a battery of muscle performance criteria in­
cluding muscle contraction and relaxation velocities, load values. 
46 
g 
amplitudes and latencies. This study was done to evaluate and charac­
terize the functional effects of CPA on cardiac muscle through the uti­
lization of this biological assay system. 
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MATERIALS AND METHODS 
Turkey papillary muscle preparation Nine turkey poults (8-14 
weeks old. Broad Breasted White) were utilized In this study. Each 
bird was anesthetized with sodium pentobarbital (65 mg/kg) just prior 
to tissue preparation. The heart was removed and left ventricular 
papillary muscles were cut to dimensions of 1 mm x 1 mm x 7-10 mm as 
9 previously described. 
Equipment Papillary muscles were mounted in the Inner chamber of 
a double chambered constant-temperature bath. The mounting technique, 
apparatus and chamber fluid circulation was performed as previously 
Q 
reported. The chamber fluid was a modified Krebs-Henseleit (K-H) 
solution containing: NaCl (118 mM); KCl (4.7 mM); MgClg (1.2 mM); 
Na2H2P04*H20 (11 mM); NaHCOg (24.0 mM); CaClg' 6H2O (1.7 mM); glucose 
(4.5 mM); pH 7.40. Chamber fluid was circulated by an individual rate 
controlled pump. The total system required 10 ml of fluid. The fluid 
was aerated with 95% O2 - 5% CO2, maintained at 31° C and 7.4 pH. 
Silver electrodes were arranged on each side of the muscle. The muscle 
was stimulated with 20 mVolts, at a frequency of 10 pulses per second, 
with 5 msec duration. Time, electrical stimulus, and muscle con­
tractions were recorded with a 4-channel Beckman polygraph (No. 611, 
Beckman Instruments Inc., Electronic Instruments Division, Schiller 
Park, IL). 
CPA toxin Purified crystalline CPA was produced according to 
previously described methods.Purity was determined to be 95% by 
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thin-layer chromatographic and gas chromatographic mass spectral analy­
ses conducted In another laboratory (R. J. Cole, USDÂ, ARS, National 
Peanut Research Laboratory, Dawson, 6Â). The CPA was dissolved In 
ethanol at a concentration so that 6 ul of solution contained the de­
sired quantity of CPA to give a muscle chamber solution concentration 
of 6 ug/ml. 
Contractile studies Muscles were stabilized for 2-2 1/2 hours 
while contracting Isotonlcally In K-H solution. Following stabilization, 
the length of muscle that produced maximal contraction (L max) was de­
termined for each muscle preparation. The procedures for determining L 
max and 90% L max were as previously described. 
Seven parameters of muscle function were obtained from experiments 
using the nine turkey papillary muscles. These parameters were: the 
maximum weight a muscle could lift (P^ ); maximum contraction and re­
laxation velocities (V max); time delay or latency between electrical 
stimulation and initiation of contraction (Lat 1), peak contraction 
(Lat 2), or completion of contraction and relaxation (Lat 3) and dis­
tance a weight was lifted (Work). V max was determined by the Hill 
12 
equation from contraction or relaxation values generated by each 
afterload curve. Latency values were measured from recordings of con­
traction curves produced by the preload weight or the 90% of L max 
weight (where 25 mm - 1000 ms). Each set of muscle afterload data was 
normalized by length, cross-sectional area, and P^  for each muscle. 
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CPA solution studies The K-H solution was prepared on the ex­
perimental day. Following the completion of a 2 1/2 hour Isotonic 
stabilization period and preload determination of each muscle, the K-H 
solution was changed. The order of muscle exposure to solutions was 
K-H solution (K-H), K-H solution with 6 ul ethanol (K-H + E), K-H 
solution with 6 ul ethanol plus 6 ug/ml CPA (K-H + E CPA), and a second 
K-H solution (K-H). The solution was changed following the completion 
of an afterload curve for each solution. The solution In the chamber 
and tubing was quickly drained and the next solution was added. During 
these solution changes, the muscle was maintained by bathing with K-H 
solution applied with a disposable pipette. The muscle was allowed to 
equilibrate in each solution for a 15 minute period before an afterload 
curve was generated. 
Statistical analysis Afterload curve contraction and relaxation 
velocity data were described using a 3rd degree polynomial equation. 
The V max, P^ , Work and latency values were subjected to an analysis 
of variance that considered the muscle and the four exposures as sources 
of variation. Means were compared using a least significant difference 
(P <0.05). 
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RESULTS 
The effects of CPA on muscle performance are shown in Table 1. 
These afterload data indicate that there were significant differences 
among the means of all measured parameters. Mean comparisons for each 
group of the seven significant CPA-related effects are shown graphically 
in Figure 1. We found that mean comparisons of muscle performance in 
K-H + ethanol and K-H + ethanol and CPA showed five means that were sig­
nificantly different. Those parameters were maximum contraction 
velocity, maximum relaxation velocity, P^ , latency 2 and latency 3. 
Means of latency 1 indicated a trend similar to latency 2 and 3 of 
slower completion of contraction while exposed to CPA. 
There were no significant differences among mean comparisons for 
all afterload parameters, when comparing performance in K-H + ethanol 
and CPA and the second K-H solutions. Contraction and relaxation maxi­
mum velocities, and the three latency measurements showed trends toward 
returning to base line values of the initial K-H + ethanol solutions 
(Table 1, Figure 1). When comparing the muscle's ability to do work, a 
trend of steady decline in performance was observed in all solutions 
following the initial K-H. 
In all Instances, mean comparisons between the performance in 
initial K-H and K-H + ethanol solutions were not significantly different. 
Figure 1. The effects of Cycloplazonlc acid on afterload param­
eters (means) of turkey papillary muscle bloassays. 
Experimental solutions are; K-H " Krebs-Henselelt, 
K-H+E " Krebs-Henselelt plus ethanol, K-H+E CPA • 
Krebs-Henselelt plus ethanol and Cycloplazonlc acid 
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Table 1. Mean contraction and relaxation velocities, work and latency afterload values of 
turkey papillary muscles in response to 6 ug/ml cyclopiazonic acid (CPA) 
Solutions and Sequence of Exposure 
Krebs- Krebs-
Krebs- Henseleit Henseleit Krebs- L.S.D. 
Henseleit Ethanol Ethanol + CPA Henseleit (P < 0.05) 
Contraction 
Maximum Velocity 
(mm/sec/CSA)*'b'C 0.46* 0.46* 0.33* 0.38* 0.050 
Relaxation 
Maximum Velocity 
(mm/sec/CSA)*'b'C 0.37* 0.39* 0.24* 0.27* 0.060 
P^  (mg)*'C'd 0.14* 0.14* 0.12* 0.12* 0.002 
Work (mgs.mm/CSA)* 'C 16.70* 15.60** 13.90* 13.50* 1.790 
Latency 1 (mm)*^  1.60* 1.70** 2.20*^  2.00^  0.190 
Latency 2 (mm)*^  5.70* 5.70* 6.50* 6.20* 0.230 
Latency 3 (mm)*^  10.50* 10.20* 11.30* 11.00* 0.750 
Normalized for muscle cross sectional area (CSA). 
Maximum contraction and relaxation velocities are y intercepts, determined by plotting 
velocity vs load. 
The standard errors for the means are; Con Vel (0.02), Rel Vel (0.02), (0.002), 
Work (0.59), Lat 1 (0.06), Lat 2 (0.08), Lat 3 (0.25). 
is the maximum isometric weight load of a muscle. 
Means with the same symbol are not significantly different (P < 0.05). 
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DISCUSSION 
This study demonstrates that the turkey papillary muscle evaluation 
system can be utilized to provide preliminary vitro cardiac evalu­
ation of the mycotoxln CPA. 
Our data Indicate that acute exposure to CPA at 6 ug/ml signifi­
cantly decreased five parameters of muscle performance. The five per­
formance criteria Included; maximum contraction velocity, maximum 
relaxation velocity, P^ , latency 2 and latency 3. Cycloplazonlc acid 
significantly decreased both maximum contraction and maximum relaxation 
velocities. Combining these decreased velocities with the observed 
decreased P^  delays In time to peak contraction and total time for mus­
cle contraction and relaxation suggests that the site of action Is  
Intracellular and calcium related. The onset of contraction can be 
altered by Influencing the sarcolemma. Either the action potential or 
the transsarcolemmal pulse of trigger calcium necessary to cause calcium 
release by the sarcoplasmic reticulum could be altered. Decreased re­
laxation velocity can be attributed to Impaired calcium uptake by the 
sarcoplasmic reticulum or slowed cross-bridge turn over. Calcium 
governs both the number of active cross-bridges between actln and myosin 
filaments during tension development and the rate of turn over of cross-
bridge formation.P^  represents the maximum Isometric force and 
Is proportional to the number of active actln-myosln sites capable of 
producing this force. Calcium exposes the myosin binding sites of the 
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actln filament and directly activates ATPase. Varied calcium concen­
trations have been shown to alter P* 
o 
CPA Is a lipophilic monobasic acid known to complex with divalent 
cations.* CPA alters either Ion pumps or membrane permeability.^  ^ If 
CPA complexed with calcium as It entered the cell following depolari­
zation of the cell membrane or altered cell permeability, the activa­
tion of the papillary muscle mechanical response would be greatly al­
tered and could explain portions of the effects found In the present 
study. 
The Inability of the muscles to significantly recover from ex­
posure to CPA was observed In all parameters. These results are 
strikingly different from previous work with T-2 mycotoxln and ethanol. 
Depressed muscle functions were restored after re-equlllbratlon In K-H 
solution following exposure to T-2 toxin at either 2.5 or 7.5 ug/ml.^ * 
Muscle exposure to 0.6 ul/ml of ethanol did not significantly decrease 
muscle performance. These results are consistent with previous re­
sults where muscle performance was not significantly altered following 
two consecutive exposures to 0.6 ul/ml of ethanol over a similar time 
period.This lack of recovery further suggests that the effects of 
CPA are the result of Intracellular functional and/or morphological 
changes. These results are not fully explained by CPA calcium inter­
action but support previous work that demonstrated a continual degra­
dation of ^  vivo cardiac function until terminal ventricular fibril­
lation occurred.^  
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Cycloplazonic acid did not significantly alter muscle performance 
as measured by work and latency 1. However, there was a trend towards 
decreased performance In these measurements. We attribute part of this 
lack of statistical difference to measuring sensitivities that may not 
precisely reflect exact differences In latency. 
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SUMMARY 
Isolated papillary muscles were acutely exposed to 0 or 6 ug/ral 
of CPA mycotoxln. Seven parameters of jUa vitro papillary muscle per­
formance were significantly decreased. The seven performance criteria 
were; P^ , work, maximum contraction and relaxation velocity, and times 
to Initiation, peak, and completion of contractions. Calcium and ATP 
availability appear to be responsible. In part, for these altered per­
formances. Electron photomicrographs demonstrated that CPA exposed mus­
cles had Increased numbers of swollen or lysed mitochondria. 
This study provides additional evidence that at this exposure 
level, iji vitro cardiac muscle performance Is Irreversibly decreased 
and mitochondrial morphology Is altered. 
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INTRODUCTION 
Cycloplazonlc Acid (CPA) Is a mycotoxln produced by several fungal 
species In the genera Pénicillium and Aspergillus. The toxicity of CPA 
has been experimentally demonstrated In rats, mice, rabbits, dogs, 
chickens, and plgs.^ "^ ® In vitro experiments utilizing CPA have In­
cluded tissue preparations of esophagus, jejunum. Ileum, trachea, aorta, 
vas deferens, uterus, ventricles, cell cultures of rat hepatocytes and 
pig renal epithelial cells, and sarcoplasmic reticulum vesicles from 
11-15 
rat skeletal muscle. 
The effects of CPA on the ultrastructure of rat liver has been 
studied. Oral dosages of 2.0 and 4.0 mg/kg/day resulted in swollen 
mitochondria and vesiculation of the rough endoplasmic reticulum. 
Mitochondrial membranes were intact in all sections examined.Ultra-
structural changes were also reported in guinea pigs dosed at total 
doses of 4, 8, 12, and 16 mg/kg. Lower doses resulted in limited mito­
chondrial swelling. Animals that received 12 and 16 mg/kg showed a 
dose response In severity and degree of dilated sarcoplasmic reticulum, 
swollen mitochondria, and segmental necrosis in gastrocnemius and vas­
tus lateralis musculature.^  ^ In monkeys exposed to levels of CPA up 
to 60 mg/kg/d for 16 weeks, ultrastructural changes were found in the 
capillaries of the heart and kidneys. Capillary endothelium showed 
Irregular thickening and contained cytoplasmic vacuoles or large 
fenestrations. Cytoplasms had irregular processes or long Irregular 
foldings. In myocytes focal lysis of myofibrils, mitochondrial 
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accumulation and lysosome formations were noted. Hepatocellular dla-
18 lated rough endoplasmic reticulums were also observed. 
An earlier study demonstrated that CPA decreased turkey cardiac 
19 
muscle performance following dm vitro exposure to CPA. This study 
was performed to further characterize the observed decrease In cardiac 
muscle performance and correlate physiological performance with patho­
logical changes. Electron microscopy was utilized to assess muscle 
ultrastructural changes and determine sites of injury. 
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MATERIALS AND METHODS 
Turkey papillary muscle preparation Ten turkey poults (8-14 
weeks old, Broad Breasted White) were utilized In this study. Each 
bird was anesthetized with sodium pentobarbital (65 mg/kg) just prior 
to tissue preparation. The heart was removed and left ventricular 
papillary muscles were cut to dimensions of 1 mm x 1 mm x 7-10 mm as 
20 previously described. 
Equipment Papillary muscles were mounted In the Inner chamber of 
a double chambered constant-temperature bath. The mounting technique, 
apparatus utilized and chamber fluid circulation was performed as pre-
20 
vlously reported. The chamber fluid was a modified Krebs-Henselelt 
(K-H) solution containing: NaCl (118 mM); KCl (4.7 mM); MgClg (1.2 mM); 
Na2H2P04*H20 (11 mM); NaHCO^  (24.0 mM); CaClg' 6H2O (1.7 mM); glucose 
(4.5 mM); pH 7.40. Chamber fluid was circulated by an Individual rate 
controlled pump. The total system required 10 ml of fluid. The fluid 
was aerated with 95% Og - 5% COg, maintained at 31° C and 7.4 pH. Sil­
ver electrodes were arranged on each side of the muscle. The muscle 
was stimulated with 20 mVolts, at a frequency of 10 pulses per second 
with 5 msec duration and time, electrical stimulus, and muscle contrac­
tions were recorded with a 4-channel Beckman polygraph (No. 611, Beckman 
Instruments Inc., Electronic Instruments Division, Schiller Park, IL). 
CPA toxin Purified crystalline CPA was produced according to 
21 previously described methods. Purity was determined to be 95% by 
thin-layer chromatographic and gas chromatographic-mass spectral 
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analyses conducted in another laboratory (R. J. Cole, USDA, ARS, 
National Peanut Research Laboratory, Dawson, GA). The CPA was dis­
solved In ethanol at a concentration so that when 6 ul of solution was 
added to the muscle chamber solutions, a concentration of 6 ug/ml was 
obtained. 
Contractile studies Muscles were stabilized for 2-2 1/2 hours 
while contracting isotonlcally in K-H solution. Following stabilization, 
the length of muscle that produced maximal contraction (L max) was de­
termined for each muscle preparation. The procedures for determining L 
22 
max and 90% L max were as previously described. 
Seven parameters of muscle function were obtained from experiments 
using turkey papillary muscles. These parameters were: the maximum 
weight a muscle could lift (P^ ); maximum contraction and relaxation ve­
locities (V max); time delay or latency between electrical stimulation 
and initiation of contraction (Lat 1), peak contraction (Lat 2), or com­
pletion of contraction (Lat 3) and distance a weight was lifted (Work). 
23 V max was determined by the Hill equation. from contraction or re­
laxation values generated by each afterload curve. Latency values were 
measured from one weight that corresponded to the preload weight or 90% 
of L max weight. Latency values were also derived from the contraction 
curves. Each set of muscle afterload data was normalized by length, 
cross-sectional area, and P^  for each muscle. 
CPA solution studies The K-H solution was prepared on the ex­
perimental day. Following the completion of a 2 1/2 hour isotonic 
stabilization period and preload determination of each muscle, the K-H 
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solution was changed. Muscles were randomly assigned to either a treat­
ment group of 5 muscles or a control group of 5 muscles. The order of 
muscle exposure to solutions was K-H solution (K-Hl), K-H solution with 
6 ul ethanol (K-H + E) or K-H solution with 6 ul ethanol plus 6 ug/ml 
CPA (K-H + E CPA), and a second K-H solution (K-H2). The solution was 
changed following the completion of an afterload curve for each solu­
tion. The solution in the chamber and tubing was quickly drained and 
the next solution was added. During these solution changes, the muscle 
was maintained by bathing with K-H solution. The muscle was allowed to 
equilibrate in each solution for a 15 minute period before an after-
load curve was generated. 
Electron microscopy Muscles were fixed iji situ following the 
completion of each experiment. Chamber K-H solution was drained and re-
O 
placed with cold (4 C) 2.5% glutaraldehyde fixative. Each muscle re­
mained in glutaraldehyde for 2 hours under tension from the 90% of L max 
weight. Muscles were washed three times with 0.1 M cacodylate buffer. 
The fixed tissues were allowed to come to room temperature and further 
processed in 1% osmium tetroxide in 0.1 M phosphate buffer, dehydrated, 
and embedded in plastic (Medcast, Ted Pella, Inc., Tustin, CA). One 
micron sections of cross sectional and longitudinal myofibers were ex­
amined for histological changes. Thin sections were cut with an LKB 
Ultrotome (LKB Producter AB, Stockholm-Bromma, Sweden), stained with 
uranyl acetate and lead citrate. Ultrastructural changes were assessed 
in a Philips 410 Electron Microscope (N. V. Philips Gloeilampenfabrikien, 
Eindhoven, The Netherlands). 
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Statistical analysis Afterload curve contraction and relaxation 
velocity data were fit to a 3rd degree polynomial equation. Group 
means of V max, P^ , work, and latency values were compared by analysis 
of variance. 
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RESULTS 
The effects of CPA on muscle performance indicate that there were 
significant differences among the means of all measured afterload pa­
rameters as shown In Table 1. Comparisons were considered significantly 
different at the P 0.05 level. We found that mean comparisons of 
muscle performance In K-Hl ethanol and K-H + ethanol and CPA showed 
seven means that were significantly different. Those parameters were 
maximum contraction velocity, maximum relaxation velocity, P^ , work, 
latency 1, latency 2, and latency 3. 
There were no significant differences among mean comparisons for 
all afterload parameters, when comparing performance In K-H + ethanol 
and CPA and the second K-H solutions. Contraction and relaxation maxi­
mum velocities, work, and latency 2 and 3 measurements showed trends 
toward returning to base line values of the initial K-Hl solution 
(Table 1). There were no significant differences among mean comparisons 
for any parameters, when comparing the 5 control muscles performance in 
K-Hl, K-H + ethanol and K-H2. 
Electron photomicrographs of muscles exposed to 0.6 ug CPA/ml 
bathing solution demonstrated mitochondrial changes when compared to 
control muscles. These mitochondrial changes were characterized by 
swelling (Figure 1) and cristoloysis, disorganization or lysis of 
crlstae (Figures 2, 3). These changes were not uniformly observed 
throughout muscle preparations, but no pattern of occurrence was 
Table 1. Mean contraction and relaxation velocities, P^ , work and latency afterload values of 
turkey papillary muscles (N=5) in response to (6 ug/ml) cyclopiazonic acid (CPA) 
Krebs-
Krebs- Henseleit + Krebs-
Henseleit 1 Ethanol^  + CPA Henseleit 2 L.S.D. 
Contraction 
Maximum Velocity 
(mm/sec/CSA)**b'C 0.54* 0.42* 0.40+ 0.05 
Relaxation 
Maximum Velocity 
(mm/sec/CSA)**b'C • 0.57* 0.36+ 0.39+ 0.07 
P^  (mg)*'C'd 0.23* 0.21+ 0.21+ 0.01 
Work (mgs mm/CSA)*'^  18.90* 15.50+ 15.60+ 2.36 
Latency 1 (mm)^  0.80* 1.10+ 1.10+ 0.21 
Latency 2 (mm)^  5.05 5.85+ 5.75+ 0.46 
Latency 3 (mm)*^  8.73* 10.85+ 10.68+ 0.69 
Normalized for muscle cross sectional area (CSÂ.). 
Maximum contraction and relaxation velocities are y intercepts, determined by plotting 
velocity vs load. 
Mean and individual S.E.M. are; Con Vel 0.02, Rel Vel. 0.02, (0.01), Work (0.59), 
Lat 1 (0.06), Lat 2 (0.08), Lat 3 (0.25). 
P^  is the maximum weight a muscle could lift. 
Five control muscles were exposed to 6 ul of only ethanol in K-H; there were no significant 
differences from muscles performing in K-H alone. 
Means in each row with the same symbol are not significantly different (P < 0.05). 
Figure 1. Myocardial mitrochondrial swelling from a papillary muscle 
exposed iji vitro to 6 ug CPA/ml bathing solution. 
X 14,040 

Figure 2. Myocardial mitochondrial swelling and crystolysls from 
a papillary muscle exposed vitro to 6 ug CPA/ml 
bathing solution, x 14,040 
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Figure 3. Myocardial mitochondrial disorganization or lysis of 
crlstae from a papillary muscle exposed ^  vitro to 
6 ug CPA/ml bathing solution, x 14,040 
78 
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observed, I.e., muscle core vs peripheral. The transition from areas 
with normal mitochondria to affected areas was not gradual but succinct. 
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DISCUSSION 
Acute exposure to CPA at 6 ug/ml significantly decreased all par-
19 
ameters of muscle performance. A previous study demonstrated a sig­
nificant (P ^  0.01) decrease in five muscle performance parameters; 
maximum contraction velocity, maximum relaxation velocity, P^ , latency 
2 and latency 3 following exposure to CPA. It was suggested, and fur­
ther supported by this study, that the site of CPA action was intra-
19 
cellular and calcium related. 
Electron photomicrographs comparing the 5 control and 5 CPA treated 
muscles demonstrated that intracellular changes had occurred. These 
changes were restricted to mitochondria. Affected fibers showed swollen 
and lysed mitochondria. No other disruption of myofibril morphology was 
observed perhaps because this was an acute or subacute iii vitro study. 
The altered mitochondrial morphology observed is difficult to inter­
pret. Swollen mitochondria in liver and skeletal muscle has been pre­
viously reported following exposure to CPA.^ *' Mitochondria may be 
specifically damaged by a number of factors including, metabolic in­
hibition and deficiencies of electrolytes, enzymes or substrates. How­
ever, swollen mitochondria are associated with loss of capacity to syn­
thesize ATP. A loss of ATP would also contribute to decreased muscle 
performance observed in this study. 
The effects of altered intracellular calcium levels could also con­
tribute to the significant decrease in both maximum contraction and max­
imum relaxation velocities and P . These results are consistent with 
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studies showing that CPA is a potent Inhibitor of both calcium trans­
port and calcium dependent ATPase activity of sarcoplasmic reticulum 
vesicles Isolated from rat skeletal muscle.Mitochondrial swelling 
and lysis could be explained by inhibition of calcium transport. Mito­
chondria accumulate calcium in a process that is energy coupled to 
electron transport. Electron transport energy can be used to accumu-
24 late calcium or to form ATP but not both. Venoms toxic to muscle 
often act by decreasing the uptake and binding of calcium in mlto-
25 26 
chondrla. ' Electrolyte composition disturbance by CPA could ex­
plain the mitochondrial swelling observed in this study. Mitochondrial 
swelling may occur by enhancement of cation influx and modification of 
the electrostatic barrier Imposed by the phospholipid bllayer. This 
process Involves water and metal salt Influx through the inner mlto-
27 
chondrlal membrane. 
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SUMMARY 
This Is the first report of cycloplazonlc acid toxicity in turkey 
poults. Acute exposure to CPA at 5, 10, and 20 mg/kg/d produced clini­
cal symptoms, altered clinical pathology and gross lesions. Signs of 
disease Included lethargy, ataxia, drooped head and wings, ruffled 
feathers, regurgitation, marked anorexia, decreased amount and unformed 
feces. There were decreases in total serum protein and albumin concen­
trations of poults in the two greater dose groups but no changes were 
found in serum concentrations of SDH, AST and CPK. Cycloplazonlc acid 
was found by thin-layer chromatography in extracts of the feces of all 
CPA-dosed turkey poults collected during the first 24 h period after 
initial dosing and corresponded to the dosage levels. The major gross 
lesions noted at necropsy occurred in the gastrointestinal tract and 
liver. Poults in the two greater dose groups had focal erosion of the 
proventrlculus and ventrlculus, a flbrlno-gelatinous membrane present 
in the ventrlculus, and Increased liver weights. 
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INTRODUCTION 
The mycotoxln cycloplazonlc acid (CPA), an Indole tetramic acid 
with a molecular formula of C^ QHggNgOg, was first isolated from 
Pénicillium cyclopium Westling.^  Several fungal species in the genera 
Pénicillium and Aspergillus produce CPA. Corn, peanuts, cheese and 
chicken meat have been shown to be contaminated with CPA.^  ^  
No information is available regarding the toxicity of CPA in tur­
keys; however, there are several studies of CPA toxicity in chickens. 
The EDgg of CPA for two, three and four day-old chicken embryos was 
found to be 2.4, 4.7 and 2.7 ug, respectively. The acute LD^ g in day- • 
old cockerels was found to be 21.71 mg/kg.^  Another study determined 
a 72-hour LDgg of 12.0 mg/kg for male broiler chicks and 12.1 mg/kg for 
8 9 females. Cole retrospectively speculated that the acute effects, 
hemorrhagic enteritis lesions and neurological symptoms observed in 
"Turkey X dlsease"^  ^that killed 100,000 turkey poults, were produced 
by CPA and not aflatoxln. Dose-related lowered feed conversion and 
decreased feed Intake have been reported in chronic feeding studies 
with CPA in chickens.Chickens dosed orally with 10 mg/kg lost 
weight within 24 h. By 96 h after dosing, body weight began to recover 
but birds were stunted compared to controls. Birds given 0.5 or 5.0 
mg/kg gained weight, but at significantly slower rates than controls; 
the 10 mg/kg group exhibited a subdued behavior and appeared un-
6 13 
thrifty. ' Chicks gavaged with 2 or 4 mg/kg of CPA in corn oil had 
an Increased plasma creatine kinase activity that was positively 
90 
14 
correlated with skeletal muscle degeneration. In a similar study, a 
dose-related decrease in hematocrit and plasma potassium and protein was 
Q 
noted in chicks dosed with CPA at 1, 2 or 4 mg/kg for 23 days. Deaths 
occurred at the higher doses in chickens fed CPA at 10, 50, and 100 ppm 
for 7 weeks.Post mortem examination of the birds given 100 ppm re­
vealed areas of erosion, ulceration and hyperemia of the proventricular 
mucosa. There also was excess mucus overlying the mucosal surface and 
dilation of the proventricular lumen. Birds given 50 ppm had dilation 
of proventricular lumens and apparent thickened proventricular mucosal 
surfaces. Gross lesions were not observed in birds given 10 ppm. 
Similar histologic lesions of necrosis and hemorrhage or hyperplasia of 
the proventricular mucosa was reported in chicks given CPA at 1, 2 or 
4 mg/kg. 
The purpose of this study was to characterize the clinical signs, 
gross lesions and alterations in serum chemistry associated with oral 
administration of CPA to turkey poults. 
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MATERIALS AND METHODS 
Animals Twenty, 10-wk-old, broad-breasted, white turkeys 
(Midwest Hatchery, Dike, lA) were used in this study. They were in­
dividually caged and fed (NADC Turkey Starter, Ration #517, Purina 
Mills Inc., St. Louis, MO) and watered ad libitum. 
CPA mycotoxin Purified crystalline CPA was produced according 
to previously described methods.Purity was determined to be 95% by 
thin-layer chromatographic and gas chromatographic mass spectral analy­
sis conducted in another laboratory (R. J. Cole, USDA, ARS, National 
Peanut Research Laboratory, Dawson, OA). The CPA was weighed into No. 
5 gelatin capsules for oral dosing and amounts were based on daily bird 
weights. 
Experimental design Turkeys were randomly assigned to individ­
ual cages and 4 groups of 5 turkeys each at dosages of 0, 5, 10, and 20 
mg/kg/d of CPA toxin. The birds were acclimated for 10 days before 
dosing began. Each poult was dosed daily for 2 days with a balling 
gun. A ten ml blood sample was obtained Just prior to dosing and at 
end of the experiment. Blood samples were centrifuged and serum was 
removed for storage at -70° C. Fecal material was collected from each 
bird for the first 24 hours and extracted for CPA analysis according to 
previously described methods.Briefly, 100 gm of feces was mixed with 
25 gm of diatomaceous earth and 200 ml of distilled HgO before acidifi­
cation with 2 ml of 12N HCL. This mixture was extracted with 300 ml 
CHCLg by shaking for 1 h at 300 rpm. Extracts were recovered by 
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filtering through fluted filter paper collecting only the CHClg layer. 
The emulsion layer was washed with 100 ml CHClg and this CHCl^  was 
added to the previous extract. Combined extracts were filtered through 
#1 Whatman paper into evaporation flasks and evaporated to dryness 
under vacuum. The residue was transferred quantitatively to a 2-dram 
vial with CHClg, the solvent was evaporated to dryness under flowing 
nitrogen at 50° C and samples were stored at -80* C. Prior to thin-
layer chromatographic (TLC) analysis samples were reconstituted in 
CHClg. Two spiked samples, a control, and a feed sample were also ex­
tracted. Birds were weighed, necropsled and organs weighed 48 hours 
after administration of the initial dose. 
Fecal CPA analysis Extracted samples were analyzed by TLC for 
the presence of CPA. These analyses were performed on precoated silica 
gel 60 F-254 plates (5 by 10 cm; EM Laboratories, Inc., Elmsford, NY). 
Internal and external standards of CPA were Included on each plate. 
Plates were developed (20 cm) in ethyl acetate, methanol, ammonium 
hydroxide (85-10-10), sprayed with dlmethyl-amlno-benzyaldehyde in 
ethanol (2% solution), dried, sprayed with 50% ethanollc sulfuric acid, 
and heated to 110* C for 20 mln. CPA was detected visually as a blue 
spot and the quantity determined by visual comparison with the standard 
series. 
Clinical pathology Serum sorbitol dehydrogenase (SDH), aspar­
tate amino transferase (AST), creatine phosphokinase (CPK), albumin (Al) 
and total protein (TP) were determined using a centrlflcal analyzer 
(Rotachem Ila centrlflcal analyzer, Travenol Labs, Inc., Deerfield, IL). 
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Statistical analysis Group means of body weight, liver and 
spleen weights, feed consumption, fecal CPA content, serum A1 and TP 
were compared by analysis of variance. 
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RESULTS 
Clinical observations Clinical signs developed within 24 h 
after Initial dosing In the turkey poults given CPA at 10 and 20 mg/ 
kg/d. These were lethargy, ataxia, drooped head and wings, ruffled 
feathers, regurgitation, anorexia, and unformed plus decreased amounts 
of feces. Inactivity progressed to recumbency. Poults In the 20 mg/ 
kg/d group were killed in extremis 30 h after Initial dosing. All 
poults in the 10 mg/kg/d group appeared weak and lethargic the final 
24 hours before death. 
The difference in rate of body weight gain between control and 
the 2 greatest dosage groups was significant (Table 1, Fig. 1). 
Turkeys given 5 mg/kg/d appeared healthy and there was no significant 
difference in rate of body weight gain when compared to controls. 
Feed intake was reduced with increasing doses of CPA. Reduced 
feed consumption was significantly obvious in the 20 and 10 mg/kg/d 
groups by 24 h and was more marked by 48 h. An average of only 7.2 mg 
of feed was consumed by the 20 mg/kg/d group during the experiment 
(Table 1). There was no significant difference in feed consumption 
between the control and 5 mg/kg/d groups. 
Gross lesions and organ weights At post mortem examination, 
poults given 10 and 20 mg CPA/kg/d had focal erosions of the pro-
ventriculus and ventrlculus plus the presence of a dlptherltlc fibrino-
gelatinous membrane in the ventriculus. Poults given the highest doses 
had duodenal focal necrosis, enlarged gall bladders and 7 of 10 birds 
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Table 1. Mean body weight (bw), feed Intake, liver, and spleen weight 
of turkey poults given oral cycloplazonlc acid 
Dosage Group (mg/kg/d) 
0 5 10 20 L.S.D. 
24 h Body 
Weight Change(g) 
59.60* 55.40* -28.20^  -46.60+ 33.70 
48 h Body 
Weight Change(g) 
54.80* 32.40* -66.20^  -61.80^  27.20 
24 h Feed 
Intake (g) 
119.40* 107.00* 24.60^  o
 
o
 
20.40 
48 h Feed 
Intake (g) 
85.20* 80.40* w
 
o
 
o
 
0.20^  10.00 
Liver Weight 
(% bw) 
2.10* 2.46** 2.84^ 9 3.00^  0.44 
Spleen Weight 
(% bw) 
0.10* 
* 
0.11 0.09* 0.09* 0.05 
*t$ 
Means with the same symbol are not significantly different. 
Figure 1. Change In the means of body weight (mg) of turkey poults 
(5/dosage group) given oral CPA. The 2 highest dosage 
groups were significantly different from the 5 mg/kg/d 
and control groups (p < 0.05) 
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• 24h 
• 48h 
0 5 10 20 
Dose of CPA (mg/kg/d) 
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had bloody and watery colon contents. Gross lesions were not found In 
either the 5 mg/kg/d or the control groups. 
Liver weights expressed as a percentage of body weight showed a 
dose-related trend (Table 1). Significant differences were noted when 
comparing the control group to the 10 and 20 mg/kg/d groups. There was 
no significant differences when comparing the control and 5 mg/kg/d 
groups or the 5 and 10 mg/kg/d groups. Spleen weights were not signif­
icantly different among any of the treatment groups. 
Fecal CPA analysis Fecal CPA content increased with each in­
crease in dose. When comparing the 20 and 10 mg/kg/d groups, the in­
creases were significantly different with fecal CPA content of the 
20 mg/kg/d group twice that of the 10 mg/kg/d group (Table 2). The 
amounts of CPA In the feces of the 10 and 5 mg/kg/d groups were also 
significantly different. There was no significant difference between 
the 0 and 5 mg/kg/d; however, as expected, CPA was not present in un­
treated poults' feces. 
Serum proteins and enzyme analysis Total serum protein and 
albumin concentrations in serum were decreased by increasing doses of 
CPA given to the poults. Significant (P < 0.05) decreases were noted 
at the 10 and 20 mg/kg/d levels when compared to controls and the 5 mg/ 
kg/d groups. Serum SDH, AST and CPK concentrations were not signifi­
cantly changed (Table 2). 
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Table 2. Mean albumin, total protein, fecal cycloplazonlc acid (CPA) 
content of turkey poults given oral CPA 
Dosage Group (mg/kg/d) 
0 5 10 20 L.S.D. 
Albumin 1.08* 1.03* 0.60^  0.68^  0.17 
(g/100 ml) 
Total Protein 3.48* 3.10* 1.68^  1.88^  0.45 
Fecal CPA 0* 3.60* 16.80^  34.30* 6.00 
Content 
(ug/g) 
Means with the same symbol are not significantly different. 
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DISCUSSION 
Acute exposure to CPA produced clinical signs within 24 hrs of 
Initial dosing In the 10 and 20 mg/kg/d groups. These clinical signs 
of lethargy, decreased weight gain, and decreased feed Intake were 
similar to those previously reported In chlckens*'^  ^ Ataxia, regurgi­
tation and unformed feces due to CPA Ingestion has not been previously 
described in birds. The regurgitation, decreased feed intake, and 
weight loss could all be partially related to the lesions present in 
the ventriculus. The diptheritic membrane present in all (10/10) poults 
in the 10 and 20 mg/kg/d groups was extensive enough to partially pre­
vent deglutition. Death was Imminent In the 20 mg/kg/d group and, 
therefore, were killed at 30 h post dosing. All of the birds were re­
cumbent, and had not eaten for at least 12 h prior to the time they 
were killed. Cycloplazonic acid was found in feces collected during 
the first 24 h period and corresponded in a linear relationship to the 
dosage levels. Apparently, following dosing,.significant amounts passed 
through the bird to the feces. This is in agreement with Norred and 
coworkers^  ^ finding's that radio-labeled CPA was readily absorbed from 
the gut, its major route of excretion was fecal, and it had a half life 
of 43 + 12 hrs following administration. 
Relatively few gross lesions have been observed in animals follow­
ing exposure to CPA. Chickens fed 50 or 100 ppm had lesions in the 
gastrointestinal tract.Thickened mucosa and dilated lumens were 
noted in the proventrlcull of birds fed 50 ppm dietary CPA. Birds from 
V  
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the 100 ppm group had proventrlcular mucosal erosion and hyperemia, 
Similar gross lesions Including; hemorrhage, necrosis and hyperplasia of 
proventrlcular mucosa were reported in chickens gavaged with 1, 2 or 
4 mg/kg CPA.^  ^ Focal erosions present in the proventrlculus and ven-
triculus in our turkey poults given 10 and 20 mg CPA/kg/d were similar 
to lesions previously described. The presence of a fibrlnogelatinous 
diptheritic membrane in the ventriculus may represent a local response 
to exposure to relatively high levels of toxin. Because this was an 
acute study, lesion sequella, i.e., thickened proventrlcular mucosa re­
ported in more chronic studies, would not have had time to manifest 
themselves. 
Q 
Wilson ^  jd. reported some changes in clinical pathological val­
ues in chickens following CPA exposure. In chicks dosed with CPA at 1, 
2 or 4 mg/kg for 23 days, a dose-related decrease in plasma potassium 
and protein was noted. In the present study decreased total serum pro­
tein and albumin was observed in the 10 and 20 mg/kg/d groups. Duncan 
17 
and Presse state that hypoprotelnemla may be caused by hemorrhage, 
loss in urine, production loss, or intestinal loss. Some blood was 
present in the feces of poults in this study but no frank hemorrhage 
was observed. Amounts of protein lost in the urine/feces is unknown. 
Decreased production appears unlikely because, this was an acute, 30-48 
h study and SDH levels were not decreased indicating the liver was 
functional. Therefore, intestinal loss appears to be the most likely 
explanation of decreased total serum protein and albumin. The fibrlno­
gelatinous diptheritic membrane in the ventriculus and upper duodenum 
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represent protein loss that could account for these decreases* In cases 
of protein loss from serum, albumins are the smallest and first protein 
to move across the intestinal wall with globulins and fibrin crossing 
18 later. In this study, albumin levels were decreased and corresponded 
with increased dose. 
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SUMMARY 
Effects of cycloplazonlc acid (CPA) on feed Intake, water Intake, 
hematological values and microscopic lesions were evaluated. Three 
groups of turkey poults, each containing 8 poults, were given either 0, 
5, or 10 mg CPA/kg/d orally for 2 days. Poults given 10 mg CPA/kg/d 
had a significant (P < 0.05) decrease In body weight, feed consumption 
and water Intake when measured at 24 and 48 hours. Turkeys given 10 
mg/kg had significant hematological changes which included leukocytosis, 
heterophllia and lymphocytosis. Histopathologic changes consisting of 
mucoflbrlnous necrotizing proventrlculltls and ventriculitis, multifocal 
ulcerative enteritis, and multifocal necrotizing hepatitis occurred in 
all poults dosed with 10 mg CPA/kg/d. 
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INTRODUCTION 
Cycloplazonlc acid Is a mycotoxln produced by several species In 
the genera Aspergillus and Pénicillium. The extent of CPA contami­
nation of food and feed has not been fully evaluated; however, corn, 
peanuts, cheese and millet have been shown to be naturally contami­
nated with CPA.^  ^  
The role of CPA In animal and human disease has not been estab­
lished. The toxicity of CPA has been demonstrated In several animal 
species Including rats, mice, guinea pigs, chickens, dogs, rabbits, 
pigs and monkeys.^  Experimental toxicosis Is predominantly char­
acterized by gastrointestinal ulceration, splenic atrophy and necro­
sis, nephropathy, and hepatic and myocardial necrosis. 
There appears to be species differences following oral exposure to 
CPA. These differences are dose sensitivity and affected target organs. 
In laboratory animals, the most commonly reported lesions include; he­
patic vacuolation and necrosis, renal tubular nephrosis, splenic hem­
orrhage and necrosis, skeletal muscle degeneration and myocardial hya-
5"8 19 21 line degeneration. ' ' In pigs and chickens, gastrointestinal hy­
peremia, mucosal hyperplasia, ulceration and necrosis were reported in 
22 24 30 
addition to lesions similar to those noted in laboratory animals. ' ' 
In orally exposed monkeys mild renal tubular atrophy with protein casts 
31 28 
was noted. Dogs are the most sensitive species tested for toxicity 
to CPA. In feeding studies, the major dose-related microscopic lesions 
were dermal necrosis, infarcts and ulceration and necrosis of the 
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gastrointestinal tract. Splenic lymphoid depletion and necrosis was 
also reported. 
Several studies have reported lesions In the heart. Purchase^  
first reported cardiac lesions of hyaline or coagulatlve degeneration 
of rat myocardium following CPA exposure to oral doses ranging from 30 
to 82.6 mg/kg. In chickens fed 50 and 100 ppm dietary CPA on an ad 
libitum basis, there was subacute to chronic Inflammation of the myo-
22 
cardlum noted at both dosing levels. 
Weekly dosages of 12 or 21 mg/kg in rats produced additional 
pathological changes of the myocardium which Included cellular degener­
ative changes of enlarged pleomorphic nuclei, with marginatlon of 
chromatin.^  
Myocardial lesions were present in two monkeys treated with CPA; 
doses up to 60 mg/kg caused focal degenerative changes of focal atrophy 
31 
and Intracellular organelle disruption. In contrast, no heart lesions 
were noted in CPA studies where oral doses were 0.1 or 4 mg/kg in 
rats,^ * 1, 2, or 4 mg/kg in broiler chicks,0.05, 0.25, 0.5, or 1.0 
28 OA 
mg/kg in dogs, and 0.01, 0.1, 1.0, or 10 mg/kg in piglets. 
Few studies have reported hematological observations. Hill et 
12 
al. reported that in rats given 0.1, 1.0 and 5.0 mg CPA/kg for 28 
days, there was higher mean neutrophil counts and lower mean eosinophil 
and lymphocyte counts than in controls. Packed cell volume was unal­
tered. Cyclopiazonlc acid did not affect the degree of cellularlty, 
myeloid to erythrold ratio and presence of all stages of maturation in 
bone marrow smears. Dose-related hematological changes in dogs dosed 
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at 0.05, 0.5 and 1.0 mg/kg, consisted of leukocytosis, neutrophilia, 
28 lymphopenia, and monocytosis. 
The purpose of this study was to characterize pathological and 
hematological changes and to further characterize previously observed 
32 dehydration that we associated with oral administration of CPA to 
turkey poults. 
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MATERIALS AND METHODS 
Animals Twenty-four, 10-wk-old, broad-breasted, white turkeys 
(Midwest Hatchery, Dike, lA) were used in this study. They were in­
dividually caged and fed (NADC Turkey Starter, Ration #517, Purina 
Mills Inc., St. Louis, MO) and watered ad libitum. 
CPA mycotoxin Purified crystalline CPA was produced according 
22 to previously described methods. Purity was determined to be 95% by 
thin-layer chromatographic and gas chromatographic mass spectral analy­
sis conducted in another laboratory (R. J. Cole, USDA, ARS, National 
Peanut Research Laboratory, Dawson, GA). The CPA was weighed into No. 
5 gelatin capsules for oral dosing and amounts were based on daily 
bird weights. 
Experimental design Turkeys were randomly assigned to individ­
ual cages and 3 groups of 8 turkeys each at dosages of 0, 5, and 10 mg/ 
kg/d of CPA toxin. The poults were acclimated for 10 days before dosing 
began. Each poult was dosed daily for 2 days with a balling gun. 
Feed consumed and water intake was measured daily. Poults were weighed, 
blood samples were collected, and the poults were necropsied 48 hours 
after administration of the initial dose. Prepared blood smears were 
stained with the Dif-Quick method (American Scientific Products, McGaw 
Park, IL 60085) for differential counts. Total WBC counts were deter­
mined on fresh whole blood with the Unopette Test 5877 (Becton-Dickinson 
and Company, Rutherford, NJ 07070). 
113 
Hlstopathology Portions of liver, heart, spleen, brain, cervi­
cal spinal cord and gastrointestinal tissues were fixed in 10% formalin, 
embedded In paraffin, sectioned at 5 urn, stained with hematoxylin and 
eosln (H & E) stain and examined by light microscopy. 
Electron microscopy Cardiac muscle tissue was fixed with cold 
(4° C) 2.5% gluteraldehyde for 2 hours. Muscles were washed three times 
and refrigerated in 0.1 M cacodylate buffer. The fixed tissues were 
allowed to come to room temperature and further processed in 1% osmium 
tetroxide in 0.1 M phosphate buffer, dehydrated, and embedded in plastic 
(Medcast, Ted Pella, Inc., Tustin, CA). One micron sections of cross 
sectional and longitudinal myoflbers were examined for histological 
changes. Thin sections were cut with an LKB Ultrotome (LKB Producter 
AB, Stockholm-Bromma, Sweden) and stained with uranyl acetate and lead 
citrate. Ultrastructural changes were assessed from Images using a 
Philips 410 Electron Microscope (N. V. Philips Gloeilampenfabrlkien, 
Eindhoven, The Netherlands). 
Statistical analysis Group means of body weight, feed con­
sumption, water consumption, and hematological differential counts were 
compared by analysis of variance. 
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RESULTS 
Clinical signs Clinical signs, similar to those described in 
32 
an earlier study, developed in the turkey poults given CPA at 10 mg/ 
kg/d. These were lethargy, ataxia, drooped head and wings, ruffled 
feathers, regurgitation, anorexia, dehydration and decreased amounts of 
unformed feces. All poults in the 10 mg/kg/d group appeared weak and 
lethargic during the final 24 hours before death. Turkeys given 5 
mg/kg/d appeared healthy. Body weight, feed consumption and water in­
take was significantly reduced in poults given 10 mg CPA/kg when meas­
ured at 24 and 48 h (Table 1). There were significant reductions in 
feed intake and body weight by 48 h in the 5 mg/kg/d group. 
Hematological findings The 10 mg/kg dose group had signifi­
cantly altered leukograms which had higher mean leucocyte, heterophil 
and lymphocyte counts than did the 5 mg/kg/d dose group or controls 
(Table 2). The 5 mg/kg/d group had a higher mean heterophil count as 
compared to controls, but the difference was not significant. 
Microscopic lesions Microscopic lesions were limited to the 
liver and gastrointestinal tract of treated birds. No changes were 
found In heart, spleen, brain, or spinal cord tissues. Microscopic 
gastrointestinal lesions were present in all poults (8/8) in the 10 mg/ 
kg/d group. They consisted of a mucofibrlnous necrotizing proventrlcu-
litis (Figure 1) and ventriculitis (Figure 2). Lesions were accompanied 
by mucosal and submucosal edema and hemorrhage (Figures 3, 4), and 
swollen ventricular glandular cells. Diffuse but multifocally prominent 
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Table 1. Mean body weight (bw), feed Intake, and water Intake 
of turkey poults given oral cyclopiazonlc acid for 2 days 
Dosage Group (mg/kg/d 
10 L.S.D. 
•k _ * 
24 h body 62.8 71.8 -69.3'' 27.3 
weight change(g) 
48 h body 72.4* 1.6^  -134.1* 65.6 
weight change(g) 
24 h feed 
intake (g) 
48 h feed 
Intake (g) 
24 h water 
intake (g) 
48 h water 
intake (g) 
140.8* 142.0* 9.4^  29.3 
177.3* 117.8^  7.6* 50.2 
426.4* 456.6* 160.0^  78.0 
582.1* 455.5* 105.6^  130.2 
^ + 6  
Means with the same symbol are not significantly different. 
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Table 2. Mean hematological values of turkey poults given oral 
cyclopiazonic acid for 2 days 
Dosage Group (mg/kg/d) 
Item 0 5 10 
(n-8) (n-8) (n"7) 
WBC 
(cell X lOT^ /ul)* 
278 + 60* 290 + 60* 870 + 64^  
Lymphocytes _ 
(cell X lOT^ /ul)* 
132 + 23* 103 + 23* 223 + 24^  
Heterophils , 
(cell X lOT^ /ul)* 
130 + 40* 182 + 40* 588 + 43^  
*Mean and S.E.M. x 10 
Means with the same symbol are not significantly different. 
Figure 1. Proventrlculus of a turkey poult given CPA orally at 
10 mg/kg/d for 2 days. Mucosal and submucosal necrosis, 
hemorrhage and edema evident. Hematoxylin and eosln. 
Bar " 1 mm 
Figure 2. Ventrlculus of a turkey poult given CPA orally at 
10 mg/kg/d for 2 days. Mucosal and submucosal necrosis, 
edema and hemorrhage evident. Hematoxylin and eosln. 
Bar - 1 mm 

Figure 3. Ventrlculus of a turkey poult given CPA orally at 
10 mg/kg/d for 2 days. Mucosal glands with edema 
and Increased numbers of heterophils. Hematoxylin 
and eosln. Bar - 40 um 
Figure 4. Ventrlculus of a turkey poult given CPA orally at 
10 mg/kg/d for 2 days. Increased numbers of heterophils 
associated with swollen mucosal glands and edematous 
lining. Hematoxylin and eosln. Bar - 40 um 
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Increases In numbers of heterophils and fewer macrophages and eosino­
phils were also present In the mucosa and submucosa Interstltlum and 
around vessels throughout the section (Figure 5). Fibrinous vasculitis 
was occasionally seen. Also present was acute multifocal epithelial 
degeneration and erosion of villous tips (Figure 6) limited to the duo­
denum and Jejunum. Villi were also mildly hyperemia with a mild In­
crease In heterophils present In the lamina propria. No remarkable 
changes were observed In the Ileum, ceca and colon. Five of the eight 
poults In the 5 mg/kg/d group had similar but markedly less pronounced 
changes In the proventrlculus and ventrlculus. There were no signifi­
cant duodenal, Jejunal or Ileal lesions In the 5 mg/kg/d or control 
poults. 
Hepatic lesions were present In all poults (8/8) In the 10 mg/kg/d 
group. They consisted of bile duct proliferation (Figure 7) and In­
creased granulocytes and macrophages associated with sinusoids and 
large bile ductd. A mild multifocal granulomatous hepatitis (Figure 8) 
was also noted. Slight bile duct proliferation was noted In two (2/8) 
poults In the 5 mg/kg/d group. No other hepatic changes were noted In 
either the 5 mg/kg/d or control groups. 
No changes were seen In electron photomicrographs of cardiac 
papillary muscles from any treatment or control poults. 
Figure 5. Increased numbers of granulocytes in the submucosa 
and around a vessel In a turkey poult given CPA 
orally at 10 mg/kg/d for 2 days. Hematoxylin and 
eosln. Bar • 40 urn 
Figure 6. Epithelial degeneration and erosion of duodenal villous 
tips in a turkey poult given CPA orally at 10 mg/kg/d 
for 2 days. Hematoxylin and eosln. Bar - 40 um 
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Figure 7. Liver of a turkey poult given CPA orally at 10 og/kg/d 
for 2 days. Bile duct proliferation with Increased 
numbers of granulocytes Is present. Hematoxylin and 
eosln. Bar = 40 urn 
Figure 8. Focal granulomatous hepatitis from a turkey poult given 
CPA orally at 10 mg/kg/d for 2 days. Hematoxylin and 
eosln. Bar " 40 um 
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DISCUSSION 
Acute oral exposure of CPA to turkey poults caused severe clinical 
signs, hematological changes and histologic lesions. Cycloplazonlc 
acid caused a significant (P ^  0,05) depression In weight gain, feed 
consumption and water Intake by 24 h, In turkey poults given the 10 mg/ 
kg/d dose. By 48 h, poults In the 5 mg/kg/d group had significantly 
decreased weight gain and feed consumption. Decreased weight gain and 
22 25 feed Intake has also been reported In chickens. ' The decreased 
water Intake, feed Intake and weight loss could be related to lesions 
present In the proventrlculus and ventrlculus. The edema, thickened 
lining, and swollen glandular cells was extensive enough to partially 
prevent deglutition. 
Clinical hematologic results were significantly altered at the 10 
mg/kg/d exposure level. Both treatment groups had a dose-related 
leukocytosis and heterophllia with only the 10 mg/kg exposure group 
Increases being statistically significant. A significant lymphocytosis 
was also present in the highest treatment group. Leukocytosis is often 
33 
associated with massive tissue necrosis. Gastrointestinal necrosis 
could have contributed to this response. The leukocytosis with hetero­
phllia and no left shift or increased Immature leukocytes suggests that 
poults in both treatment groups were also stressed. These findings are 
consistent with the observed gastrointestinal necrosis and lethargy/re­
cumbency. Our findings are consistent with hematological observations 
12 28 
of neutrophilia in dogs and rats exposed to CPA, ' and leukocytosis 
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reported In dogs. However, lymphopenia was also reported in both spe­
cies following more chronic exposures of 28 days (rat) and 90 days 
(dogs). 
Our histopathologic findings agree with observations In other 
studies. Purchase reported the effects of oral and intraperitoneal ad­
ministrations of single doses of CPA in rats included single cell to 
22 focal areas of hepatic necrosis. Borner et. al» also reported focal 
hepatic necrosis and proventricular hyperemia and ulceration in broiler 
24 
chicks fed CPA contaminated feed for 7 weeks. In another study, 
oral gavage with CPA at 4 mg/kg for 23 days produced a similar lesion 
of necrosis and hemorrhage or hyperplasia of proventricular mucosa and 
hepatocellular vacuolation. The localized necrosis in the upper gastro­
intestinal tract and liver may Indicate a direct toxic effect of CPA. 
28 Neuhrlng and coworkers reported these lesions in a 90 day study with 
dogs and suggested that this is due to ischemia resulting from vascular 
damage and thrombosis. Pigs given 10 mg/kg for 14 days, had microscopic 
lesions which included necrotizing gastroenteritis and focal hepato-
30 
cellular necrosis. Our findings demonstrate that at similar dose 
levels these lesions occur earlier than has previously been reported. 
The absence of myocardial lesions was disappointing. Studies uti­
lizing higher exposure levels have reported cardiac lesions. In an 
34 
earlier study, jjn vitro exposure to CPA resulted in mitochondrial 
5 7 31 
ultrastructural changes. Apparently exposing rats * and monkeys to 
doses of CPA 2 12 mg/kg produces cardiac lesions. In our study with 
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turkeys and studies of rats,^ * chicks,dogs^ ® and piglets^  ^exposed 
to CPA levels ^  10 mg/kg, no cardiac lesions were noted. 
The 3 ^  vivo studies In which there was reported cardiac lesions 
were of longer duration, with total oral doses exceeding that of the 
present study's dose of 10 mg CPA/kg. Perhaps a longer duration of 
dosing using doses similar to those utilized In this study or higher 
doses could result in cardiac lesions in turkeys. However, the doses 
utilized in this study resulted in a severe clinical response and 
graphic histopathologic changes in the gastrointestinal tract and liver 
which would preclude doses this high in this species. 
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GENERAL SUMMARY AND DISCUSSION 
The toxicity of CPA has been demonstrated In several animal 
species including rats, mice, guinea pigs, dogs, rabbits, pigs and 
monkeys.^  There are a few studies of CPA toxicity in 
18~20 22 23 
chickens; ' ' however, no information is available regarding the 
toxicity of CPA in turkeys. In this study, turkey heart muscle was 
utilized as a model to test the acute ^  vitro effects of CPA on iso­
lated muscle performance. Muscle performance was evaluated and cor­
related with pathologic changes. The JLn vivo effects of acute CPA ex­
posure were studied in turkey poults. 
In the first study, it was demonstrated that an JLn vitro biologi­
cal assay system, that utilized turkey papillary muscle, could function 
in an Isolated chamber containing oxygenated, pH-regulated, modified 
Krebs-Henselelt solution. Baseline information on vitro performance 
of turkey papillary muscle preparations was established. It was then 
demonstrated that different calcium concentrations affect muscle con­
traction and relaxation velocities, load values and latencies. 
In the second study, the Jin vitro biological assay system was uti­
lized to evaluate the effects of cyclopiazonic acid mycotoxin on car­
diac muscle performance. Acute exposure to CPA at 6 ug/ml of bathing 
solution significantly decreased five performance criteria of vitro 
papillary muscle. These criteria were: maximum weight a muscle could 
lift, maximum contraction velocity, maximum relaxation velocity, time 
to peak contraction and total time for muscle contraction and 
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relaxation. These altered performances appeared to be Intracellular 
changes partially associated with calcium availability and were Ir­
reversible suggesting that physlopathologlcal changes occurred follow­
ing acute CPA exposure. 
Results of the third study further characterized the observed de­
crease In muscle performance seen In the second study and correlated in 
vitro muscle performance with pathological changes. Isolated papillary 
muscles mounted In the biological assay chamber were exposed acutely 
to 6 ug CPA/ml of bathing solution. Seven parameters of Ui vitro 
papillary muscle performance were significantly decreased. The seven 
performance criteria were; maximum weight a muscle could lift, work, 
maximum contraction velocity, maximum relaxation velocity and times to 
initiation, peak and completion of contractions. Electron photomicro­
graphs demonstrated that the CPA exposed muscles, evaluated in the 
biological assay system, had increased numbers of swollen or lysed 
mitochondria. Irreversible decreased muscle performance and altered 
mitochondrial morphology were attributed to altered calcium and ATP 
availability. 
The fourth study was designed to establish a dose response for 
turkey poults and represents the first report of CPA toxicity in turkey 
poults. Clinical signs were similar to those of chickens and Included 
lethargy, ataxia, drooped head and wings, ruffled feathers, marked 
anorexia, and watery feces of reduced amount. Five turkeys given 20 
mg CPA/kg/d were killed extremis. Total serum proteins and albumin 
were decreased by CPA ingestion. Cyclopiazonlc acid was found in feces 
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collected during the first 24 h period and corresponded to dosage 
levels. The major gross lesions noted at necropsy occurred In the 
gastrointestinal tract and liver. Poults receiving 10 and 20 mg/kg/d 
had focal erosions In the proventrlculus and ventrlculus, a flbrlno-
gelatlnous membrane present In the ventrlculus, and Increased liver 
weights. The clinical and pathological findings from this study would 
33 
support the retrospective conjecture of Cole that CPA could have been 
Involved In "Turkey X disease." 
Based on the results from the third and fourth study, we then 
tested the hypothesis that Ingestion of either 5 or 10 mg CPA/kg/d by 
turkey poults for 2 days would produce cardiac myocyte ultrastructural 
changes similar to those seen In the vitro study. We also evalu" 
ated pathological and hematological changes. The results of the fifth 
study proved this hypothesis was Incorrect. 
In the fifth study, changes caused by CPA Included leukocytosis, 
heterophllla, and lymphocytosis, and histopathologic changes of muco-
flbrlnous necrotizing proventrlculltls and ventriculitis, acute multi­
focal epithelial degeneration and erosion of villous tips and mild 
multifocal granulomatous hepatitis with bile duct proliferation. Body 
weight, feed consumption and water Intake were significantly decreased 
by CPA Ingestion. No cardiac ultrastructural changes were noted. 
These studies point out that ^  vitro experiments provide Informa­
tion that Is difficult to extrapolate to vivo settings. Questions 
arise. What are the differences between ^  vitro and JUi vivo metabolism 
of CPA?, Do muscles bathed in chamber solution present different 
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binding sites for CPA?, What vivo exposure level corresponds to 6 ug 
CPA/ml bathing solution? 
These studies have contributed to a better understanding of patho­
logic, hematologic, and serologic changes in turkey poults given oral 
CPA mycotoxln. 
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